Payment overview · 2025
General Payments
$167.01
7 reported records · 4 companies
Healthcare provider profile · identity verified
Sharon Turner, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · HYDEN, KY · NPI 1073143939
Verified facts
What the public records show
CMS Open Payments records show Sharon Turner, APRN received $167.01 in general payments during 2025 across 7 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 61.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $102.11 | 61.1% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $31.49 | 18.9% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $19.64 | 11.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $13.77 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $167.01 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $102.11 | 4 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $31.49 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 328 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 276 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 143 | 34 |
| Omeprazole | Omeprazole | 134 | 29 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 116 | suppressed |
| Lisinopril | Lisinopril | 104 | 29 |
| Trazodone Hcl | Trazodone Hcl | 98 | 18 |
| Furosemide | Furosemide | 96 | 22 |
| Montelukast Sodium | Montelukast Sodium | 91 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 24 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 84 | 22 |
| Nystatin | Nystatin | 83 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 82 | 22 |
| Famotidine | Famotidine | 81 | 23 |
| Ibuprofen | Ibuprofen | 81 | 21 |
| Metformin Hcl | Metformin Hcl | 80 | 19 |
| Losartan Potassium | Losartan Potassium | 78 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 23 |
| Eliquis | Apixaban | 76 | 13 |
| Linzess | Linaclotide | 74 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 19 |
| Potassium Chloride | Potassium Chloride | 73 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 25 |
| Bumetanide | Bumetanide | 68 | 18 |
| Cefdinir | Cefdinir | 67 | 50 |
| Clonazepam | Clonazepam | 67 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 14 |
| Sertraline Hcl | Sertraline Hcl | 65 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 20 |
| Clindamycin Hcl | Clindamycin Hcl | 60 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 58 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 55 | 19 |
| Ozempic | Semaglutide | 54 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 13 |
| Carvedilol | Carvedilol | 48 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Alprazolam | Alprazolam | 42 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 33 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Mupirocin | Mupirocin | 35 | 14 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 17 |
| Lorazepam | Lorazepam | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 32 | suppressed |
| Lactulose | Lactulose | 32 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Simvastatin | Simvastatin | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | 11 |
| Glipizide | Glipizide | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 18 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nyamyc | Nystatin | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Phenytoin | Phenytoin | 15 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Metaxalone | Metaxalone | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $167.01 · 7 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, JOURNAVX, Prolastin-C Liquid, SKYCLARYS | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error